Andrew Berens

Stock Analyst at Leerink Partners

(1.79)
# 1,845
Out of 4,461 analysts
112
Total ratings
45.26%
Success rate
-7.66%
Average return

22 Stocks

Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50$97
Current: $104.23
Upside: -6.94%
Nuvalent
Apr 1, 2024
Upgrades: Outperform
Price Target: $69$110
Current: $79.25
Upside: +38.80%
Incyte
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $63.22
Upside: +23.38%
Viracta Therapeutics
Aug 15, 2023
Maintains: Outperform
Price Target: $10$5
Current: $0.63
Upside: +699.74%
Elevation Oncology
May 30, 2023
Upgrades: Outperform
Price Target: $5$8
Current: $2.56
Upside: +212.50%
Merus
Apr 17, 2023
Maintains: Outperform
Price Target: $35$48
Current: $54.84
Upside: -12.47%
BeiGene
Jan 20, 2023
Maintains: Outperform
Price Target: $236$300
Current: $156.11
Upside: +92.17%
Zymeworks
Jan 20, 2023
Maintains: Market Perform
Price Target: $8$10
Current: $8.41
Upside: +18.91%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18$20
Current: $8.79
Upside: +127.53%
Nurix Therapeutics
Dec 13, 2022
Maintains: Outperform
Price Target: $37$28
Current: $21.30
Upside: +31.46%
Arvinas
Nov 23, 2022
Maintains: Outperform
Price Target: $74$70
Current: $25.22
Upside: +177.56%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78$79
Current: $78.88
Upside: +0.15%
Zentalis Pharmaceuticals
Nov 10, 2022
Maintains: Outperform
Price Target: $42$27
Current: $4.75
Upside: +468.42%
HOOKIPA Pharma
Aug 11, 2022
Maintains: Outperform
Price Target: $4$3
Current: $0.65
Upside: +365.12%
Agios Pharmaceuticals
Aug 5, 2022
Maintains: Outperform
Price Target: $33$37
Current: $45.22
Upside: -18.18%
Cullinan Oncology
May 13, 2022
Maintains: Outperform
Price Target: $36$25
Current: $17.43
Upside: +43.43%
Compass Therapeutics
May 5, 2022
Maintains: Outperform
Price Target: $9$11
Current: $1.10
Upside: +900.00%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.20
Upside: -
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.24
Upside: -
Monte Rosa Therapeutics
Oct 14, 2021
Initiates: Market Perform
Price Target: n/a
Current: $3.63
Upside: -
Tango Therapeutics
Sep 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.10
Upside: -
Ocular Therapeutix
Jul 14, 2017
Maintains: Equal-Weight
Price Target: n/a
Current: $6.25
Upside: -